Salvianolic acid a as a multifunctional agent ameliorates doxorubicin-induced nephropathy in rats

Scientific Reports

Volumn 5, Issue 1, 2015, Pages 1-11

  Fan, Hua Ying ^a   Yang, Ming Yan ^a   Qi, Dong ^b   Zhang, Zuo Kai ^a   Zhu, Lin ^a   Shang Guan, Xiu Xin ^a   Liu, Ke ^c   Xu, Hui ^a   Che, Xin ^a  

^a YANTAI UNIVERSITY   (China)

^b YANTAI YUHUANGDING HOSPITAL   (China)

^c Shandong Target Drug Research Co Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEIC ACID DERIVATIVE; DOXORUBICIN; I KAPPA B; I KAPPA B KINASE ALPHA; LACTIC ACID DERIVATIVE; MALONALDEHYDE; MEMBRANE PROTEIN; NFKBIA PROTEIN, RAT; PODOCIN; SALVIANOLIC ACID A; SIGNAL PEPTIDE; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR RELA;

ANIMAL; BLOOD RHEOLOGY; CHEMICALLY INDUCED; COMPLICATION; DRUG EFFECTS; KIDNEY; KIDNEY DISEASES; MALE; METABOLISM; OXIDATIVE STRESS; PATHOLOGY; PHOSPHORYLATION; PODOCYTE; PROTEINURIA; SPRAGUE DAWLEY RAT; TIME FACTOR; ULTRASTRUCTURE;

ANIMALS; CAFFEIC ACIDS; DOXORUBICIN; HEMORHEOLOGY; I-KAPPA B PROTEINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY; KIDNEY DISEASES; LACTATES; MALE; MALONDIALDEHYDE; MEMBRANE PROTEINS; NF-KAPPAB INHIBITOR ALPHA; OXIDATIVE STRESS; PHOSPHORYLATION; PODOCYTES; PROTEINURIA; RATS, SPRAGUE-DAWLEY; SUPEROXIDE DISMUTASE; TIME FACTORS; TRANSCRIPTION FACTOR RELA;

EID: 85018193591     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep12273     Document Type: Article

References (43)

1. Orth, S. R. & Ritz, E. The nephrotic syndrome. New Engl. J. Med. 338, 1202–1211 (1998).
2. van den Berg, J. G. & Weening, J. J. Role of the immune system in the pathogenesis of idiopathic nephrotic syndrome. Clin. Sci. 107, 125–136 (2004).
3. Eddy, A. A. & Symons, J. M. Nephrotic syndrome in childhood. Lancet 362, 629–639 (2003).
4. Yao, X. D. Non-renal manifestations of nephrotic syndrome. Chinese Journal of Nephrology Dialysis & Transplantation 3, 496–502 (1994).
5. KDIGO. Clinical Practice Guideline for Glomerulonephritis. Kidney Int. 2, Suppl 2 (2012).
6. Wan, Y. G. & Li, C. C. Progression in the diagnosis and treatment of nephrotic syndrome. Progression in Japanese Medicine 26, 385–411 (2005).
7. Bulucu, F., Vural, A., Aydin, A. & Sayal, A. Oxidative stress status in adults with nephrotic syndrome. Clin. Nephrol. 53, 169–173 (2000).
8. Camici, M. The nephrotic syndrome is an immunoinflammatory disorder. Med. Hypotheses. 68, 900–905 (2007).
9. Sakurai, H. et al. Activation of transcription factor NF-κ B in experimental glomerulonephritis in rats. Biochimica et Biophysica Acta 1316, 132–138 (1996).
10. Sanz, A. B. et al. NF-κ B in renal inflammation. J. Am. Soc. Nephrol. 21, 1254–1262 (2010).
11. Rangan, G. K., Wang, Y., Tay, Y. C. & Harris, D. C. H. Inhibition of nuclear factor-κ B activation reduces cortical tubulointerstitial injury in proteinuric rats. Kidney Int. 56, 118–134 (1999).
12. Ruiz-Ortega, M. et al. Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa B activation and monocyte chemoattractant protein-1 synthesis. J. Immunol. 161, 430–439 (1998).
13. Gómez-Garre, D. et al. Activation of NF-κ B in tubular epithelial cells of rats with intense proteinuria. Hypertension 37, 1171–1178 (2001).
14. Shi, W., Tan, X. F., Zhao, X. C. & Chen, Y. H. Research progress in signaling pathway of podocyte injury. Chin. J. Kidney. Dis. Invest. 2, 304–309 (2013).
15. Zoja, C. et al. How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. J. Am. Soc. Nephrol. 13, 2898–2908 (2002).
16. Aizawa-Yashiro, T. et al. Novel multidrug therapy for children with cyclosporine-resistant or-intolerant nephrotic syndrome. Pediatr. Nephrol. 26, 1255–1261 (2011).
17. Zhang, F., Ou, S. T., Liu, Q. & Li, Y. The effect of Panax Notoginseng Saponins for the treatment of primary nephrotic syndrome: a meta-analysis. Medical Information 1, 92–94 (2011).
18. Zheng, R. et al. Astragaloside IV attenuates complement membranous attack complex induced podocyte injury through the MAPK pathway. Phytother. Res. 26, 892–898 (2012).
19. Dong, Y., Zhang, X., Zhang, J. & Hu, S. Effect of Salvia Miltiorrhizae injection on coagulative system in patients with primary nephrotic syndrome. China Journal of Modern Medicine 15, 2842–2844 (2005).
20. Fan, H. Y. et al. Antiplatelet and antithrombotic activities of salvianolic acid A. Thromb. Res. 126, 17–22 (2010).
21. Oh, K. S., Oh, B. K., Mun, J., Seo, H. W. & Lee, B. H. Salvianolic acid A suppress lipopolysaccharide-induced NF-κ B signaling pathway by targeting IKKβ. Int. Immunopharmacol. 11, 1901–1906 (2011).
22. Liu, G. T., Zhang, T. M., Wang, B. E. & Wang, Y. W. Protective action of seven natural phenolic compounds against peroxidative damage to biomembranes. Biochem. Pharmacol. 43, 147–152 (1992).
23. Zhang, L. et al. The effect of salvianolic acid A on nephropathy in high-fat diet fed and streptozotocin-induced diabetic rats. Chinese Pharmacological Bulletin 25(Suppl), 240–241 (2009).
24. Fang, L. H. et al. Anti-diabetic effect of salvianolic acid A and the possible mechanisms in rats with diabetes mellitus. Chinese Journal of New Drugs 20, 2063–2068 (2011).
25. Philippe, A. et al. A missense mutation in podocin leads to early and severe renal disease in mice. Kidney Int. 73, 1038–1047 (2008).
26. Gigante, A. et al. Hypercoagulability and nephrotic syndrome. Curr. Vasc. Pharmacol. 12, 512–517 (2014).
27. Chen, M. H. The appropriate time of anticoagulants for nephrotic syndrome and therapeutics selection. Chinese Journal of Nephrology Dialysis & Transplantation 21, 450–451 (2012).
28. Sahu, S., Nageswari, K., Banerjee, R. & Puniyani, R. R. Hemorheological changes in nephrotic syndrome. Clin. Hemorheol. Micro. 19, 17–20 (1998).
29. Futrakul, P. et al. A hemodynamically mediated mechanism of renal disease progression in severe glomerulonephritides or nephrosis. Clin. Hemorheol. Micro. 29, 183–187 (2003).
30. Zhan, Y. L., Wang, L., Yue, Y. H., Zhou, J. Y. & Li, X. Y. Clinical study on the effect of Xueshuantong injection on nephrotic syndrome with hypercoagulability. Chinese Journal of Traditional Medical Science and Technology 9, 262–264 (2002).
31. Shah, S. V., Baliga, R., Rajapurkar, M. & Fonseca, V. A. Oxidants in chronic kidney disease. J. Am. Soc. Nephrol. 18, 16–28 (2007).
32. Mishra, O. P. et al. Antioxidant status of children with idiopathic nephrotic syndrome. Pediatr. Nephrol. 26, 251–256 (2011).
33. Kamireddy, R. et al. Oxidative stress in pediatric nephrotic syndrome. Clin. Chim. Acta 325, 147–150 (2002).
34. Túri, S. et al. Oxidative stress and antioxidant defense mechanism in glomerular diseases. Free Radical Bio. Med. 22, 161–168 (1997).
35. Locatelli, F. et al. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol. Dial. Transpl. 18, 1272–1280 (2003).
36. Okasora, T. et al. Suppressive effect of superoxide dismutase on adriamycin nephropathy. Nephron 60, 199–203 (1992).
37. Lee, H. S. et al. Dietary antioxidant inhibits lipoprotein oxidation and renal injury in experimental focal segmental glomerulosclerosis. Kidney Int. 51, 1151–1159 (1997).
38. Pedraza-Chaverri, J., Arévalo, A. E., Hernández-Pando, R. & Larriva-Sahd, J. Effect of dietary antioxidants on puromycin aminonucleoside nephrotic sysdrome. Int. J. Biochem. Cell B. 27, 683–691 (1995).
39. Coward, R. J. et al. Nephrotic plasma alters slit diaphragm-dependent signaling and translocates nephrin, podocin, and CD2 associated proteins in cultured human podocyts. J. Am. Soc. Nephrol. 16, 629–637 (2005).
40. Dai, S. C. & Chen, N. Research progress in podocyte proteins and podocyte-related renal disease. Urology and Nephrology FMS 25, 226–230 (2005).
41. Tak, P. P. & Firestein, G. S. NF-kappaB: a key role in inflammatory diseases. J. Clin. Invest. 107, 7–11 (2001).
42. López-Franco, O. et al. Nuclear factor-kappa B inhibitors as potential novel anti-inflammatory agents for the treatment of immune glomerulonephritis. Am. J. Pathol. 16, 1497–1505 (2002).
43. Bertani, T. et al. Adriamycin-induced nephrotic syndrome in rats: sequence of pathologic events. Lab. Invest. 46, 16–23 (1982).